Correlation Between Diagnos Laboratorium and Saratoga Investama

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Diagnos Laboratorium and Saratoga Investama at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Diagnos Laboratorium and Saratoga Investama into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Diagnos Laboratorium Utama and Saratoga Investama Sedaya, you can compare the effects of market volatilities on Diagnos Laboratorium and Saratoga Investama and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Diagnos Laboratorium with a short position of Saratoga Investama. Check out your portfolio center. Please also check ongoing floating volatility patterns of Diagnos Laboratorium and Saratoga Investama.

Diversification Opportunities for Diagnos Laboratorium and Saratoga Investama

0.26
  Correlation Coefficient

Modest diversification

The 3 months correlation between Diagnos and Saratoga is 0.26. Overlapping area represents the amount of risk that can be diversified away by holding Diagnos Laboratorium Utama and Saratoga Investama Sedaya in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Saratoga Investama Sedaya and Diagnos Laboratorium is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Diagnos Laboratorium Utama are associated (or correlated) with Saratoga Investama. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Saratoga Investama Sedaya has no effect on the direction of Diagnos Laboratorium i.e., Diagnos Laboratorium and Saratoga Investama go up and down completely randomly.

Pair Corralation between Diagnos Laboratorium and Saratoga Investama

Assuming the 90 days trading horizon Diagnos Laboratorium Utama is expected to under-perform the Saratoga Investama. But the stock apears to be less risky and, when comparing its historical volatility, Diagnos Laboratorium Utama is 1.14 times less risky than Saratoga Investama. The stock trades about -0.12 of its potential returns per unit of risk. The Saratoga Investama Sedaya is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  251,000  in Saratoga Investama Sedaya on September 17, 2024 and sell it today you would lose (16,000) from holding Saratoga Investama Sedaya or give up 6.37% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Diagnos Laboratorium Utama  vs.  Saratoga Investama Sedaya

 Performance 
       Timeline  
Diagnos Laboratorium 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Diagnos Laboratorium Utama has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward-looking signals remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Saratoga Investama Sedaya 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Saratoga Investama Sedaya has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward-looking signals, Saratoga Investama is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors.

Diagnos Laboratorium and Saratoga Investama Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Diagnos Laboratorium and Saratoga Investama

The main advantage of trading using opposite Diagnos Laboratorium and Saratoga Investama positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Diagnos Laboratorium position performs unexpectedly, Saratoga Investama can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Saratoga Investama will offset losses from the drop in Saratoga Investama's long position.
The idea behind Diagnos Laboratorium Utama and Saratoga Investama Sedaya pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance